Ipratropium Bromide (C09-0927-527)

InformationIpratropium Bromide is an antagonist of M3 typemuscarinic acetylcholine receptors, used for the treatment of chronic obstructive pulmonary disease (COPD).In vitroIpratropium bromide combined with Formoterol partially protects the lungs against the chronic inflammation and airspace enlargement by reducing neutrophilic infiltration possibly via the inhibition of MMP-9 activity. Ipratropium bromide (1 nM) significantly increases [Ca(2+)](i), decreases forward scatter and increases annexin-V-binding. Ipratropium bromide treatment is followed by slight but significant increase of hemolysis. Ipratropium bromide triggers suicidal erythrocyte death or eryptosis, an effect mainly due to stimulation of Ca(2+)-entry.In vivoIpratropium dry powder inhalation (DPI) at a dose of 2400 mg/horse is an effective bronchodilator in these horses at rest but it has little effect on the airway calibre during the recovery period. Ipratropium significantly attenuates the lung lesions associated with parenchyma inflammatory cell influx and congestion observed in the cadmium treated rats. Ipratropium bromide partially protects the lungs against the inflammation by reducing neutrophilic infiltration. Ipratropium is an antagonist for pre-junctional muscarinic inhibitory receptors on pulmonary parasympathetic nerves and also confirms its potent antagonist actions on post-junctional muscarinic receptors in the airway smooth muscle in the guinea-pig. Ipratropium decreases the maximal change in pleural pressure during tidal breathing (delta Pplmax) and pulmonary resistance (RL) and increases dynamic compliance (Cdyn) in horse.Cell Datacell lines：J774.16 murine macrophage-like cell lineConcentrations：Incubation Time：Powder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C20H30BrNO3 Molecular Weight: 412.37